Prosthetic Heart Valve Market to Reach $10.48 Billion by 2030

The prosthetic heart valve devices and equipment market is projected to rise from $6.73 billion in 2025 to $10.48 billion by 2030, driven by more valve disease, more TAVR procedures and continued device innovation. North America held the largest regional share in 2025, while the market’s fastest growth is expected to come from minimally invasive and tissue-based valve options.

Why it matters: - Prosthetic heart valve devices are used to restore blood flow in patients with valvular heart disease. - The market’s growth points to rising demand for cardiac procedures that are less invasive and more durable. - Expanding use of transcatheter valve therapies could affect hospital purchasing, surgical practice and device competition.

What happened: - The Business Research Company said the global prosthetic heart valve devices and equipment market was worth $6.73 billion in 2025 and is expected to reach $7.17 billion in 2026. - The report projects the market will climb to $10.48 billion by 2030. - The report was released Aug. 25, 2026, in London. - The report is available through a full market report, and a free sample is also available.

The details: - The market is forecast to grow at a compound annual growth rate of 6.5% from 2025 to 2026. - The report projects a 9.9% CAGR from 2026 to 2030. - Historical growth was driven by more valvular heart disease cases, an aging population, broader cardiac surgery programs, higher adoption of valve replacement procedures and advances in cardiac imaging. - Future growth is expected to come from stronger demand for minimally invasive cardiac interventions, durable valve implants, expanding indications for transcatheter valve procedures, investment in structural heart disease treatments and innovation in biological valve materials. - Prosthetic heart valve devices can be mechanical or biological, depending on patient needs. - The report expects wider use of transcatheter heart valve procedures, more tissue-based valves, adoption of minimally invasive valve repair systems, improved valve durability technologies and more patient-specific valve solutions. - North America held the largest regional share in 2025. - Western Europe ranked second. - The report also covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests the market is moving from broad clinical need toward a more specialized device mix. - Growth in TAVR procedures signals that transcatheter platforms are becoming a central battleground for manufacturers. - The shift toward tissue-based and patient-specific solutions points to a market where performance, durability and customization may matter more than volume alone. - The CDC reported in May 2023 that more than 695,000 people in the US died from heart disease, or one in every five deaths, underscoring the scale of the underlying disease burden.

What's next: - More patients are expected to undergo TAVR as valvular heart disease rates rise. - Device makers are likely to keep investing in durability, biological materials and minimally invasive repair systems. - Regional competition may intensify as Asia-Pacific and other non-Western markets expand their cardiac care capacity. - The Business Research Company said its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - Prosthetic heart valve devices are shifting from a steady-growth niche into a faster-expanding market shaped by minimally invasive care, rising disease burden and stronger demand for next-generation valve technologies.